Given that SRC activation was inhibited in all HME-treated bladder cancer cell lines, we figured SRC is the primary target of HME for blocking STAT3 activation, in turn promoting bladder cancer cytotoxicity. The gene discussed is STAT3; the disease is urinary bladder carcinoma.